Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Scheipl, S; Liegl-Atzwanger, B; Szkandera, J; Rinner, B; Viertler, C; Friesenbichler, J; Bergovec, M; Leithner, A.
[Is there a magic bullet for sarcomas? : Personalised treatment for maligant tumours of bone and soft tissue].
Orthopade. 2019; 48(9): 776-783.
Doi: 10.1007/s00132-019-03790-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Scheipl Susanne
- Co-Autor*innen der Med Uni Graz
- Bergovec Marko
- Friesenbichler Jörg
- Leithner Andreas
- Liegl-Atzwanger Bernadette
- Rinner Beate
- Szkandera Joanna
- Viertler Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Personalised tumour therapies aim to selectively target pathways and structures to which a tumour shows an oncogenic addiction. This article aims to provide an overview of relevant genetic alterations in bone and soft-tissue tumours, which might serve as potential therapeutic targets for personalised medicines in the future. Recent approaches towards a personalised treatment of various tumours of bone and soft tissues are reviewed. Molecular diagnosis has become an essential tool for the characterisation of bone and soft-tissue tumours. Currently, no targeted therapies are routinely available for bone sarcomas. Denosumab is merely a symptomatic treatment for giant cell tumours of the bone. Imatinib has become the paradigm of a targeted treatment for subgroups of malignant gastrointestinal stromal tumours (GISTs) and dermatofibrosarcoma protuberans. Antiangiogenic multikinase inhibitors, various other tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are currently being evaluated in several (sub-)types of soft-tissue sarcomas. Sorafenib showed promising results in the treatment of aggressive desmoid-type fibromatosis. Histology-tailored chemotherapies did not yield superior results in a prospective randomised multicentre trial. More in-depth knowledge is required for many sarcomas to link their genetic alterations to tumorigenesis in order to develop efficient personalised treatment strategies. Clinical trial designs need to be adapted to evaluate new therapeutic strategies in these ultra-rare tumours and their various sub-types more efficaciously.
- Find related publications in this database (Keywords)
- Drug resistance
- Molecular targeted therapy
- Monoclonal antibodies
- Osteosarcoma
- Tyrosine kinase inhibitor